Publications found:
3,177
Sort by:
NOVARTIS
US$ 90.00
For the fourth quarter 2011, in line with our expectations, NVS Sales grew 5%, and core EPS advanced 8%. NVS also announced full year dividend for 2011 at CHF 2.25, which translates into a meager 2%, increase, which we think is a dampener. The 2012 guidance as well was lackluster as NVS expects net sales in ...
January 2012
2 pages
Yoghurt and Sour Milk Drinks in Switzerland
US$ 990.00
... showed a beautiful woman eating the yoghurt with the slogan, beauty to be enjoyed. Euromonitor International's Yoghurt and Sour Milk Drinks in Switzerland report offers a comprehensive guide to the ... , Condensed/Evaporated Milk, Cream, Flavoured Milk Drinks, Flavoured Powder Milk Drinks, Fromage Frais and Quark, Milk, Powder Milk, Processed Cheese, Sour Milk Drinks, Soy Beverages, Unprocessed Cheese, Yoghurt. Data ...
December 2011
65 pages
NOVARTIS - Tekturna: ALTITUDE study in high risk hypertensive patients TERMINATED
US$ 90.00
... the termination of large PhIII study (ALTITUDE) due to higher rate of adverse events and no benefits observed for patients taking Tekturna in addition to ACE ... inhibitors. Post this announcement, NVS will cease promotion of Tekturna/Tekturna products in combination with ACE inhibitors/ARB inhibitors. The event ...
December 2011
1 pages
ROCHE, GLAXOSMITHKLINE - Exciting Data on TDM1 - Will Keep Competition at Bay
US$ 140.00
... months compared to Herceptin + docetaxel (14.2 m vs. 9.2 m- Table 1). The safety data as well, is very convincing as T-DM1 cut Grade 3 or more adverse effects ... 50% (46.4% vs. 89.4%). With T-DM1 and pertuzumab arrows in its quiver, Roche is well poised to sustain its breast cancer franchise beyond Herceptin ...
September 2011
4 pages
Baby Care in Switzerland
US$ 990.00
... were marginally more babies born in 2010, combined with an improving economic state positively impacted the sales of baby care. Euromonitor International's Baby Care in Switzerland report offers ... the market is set to change. Product coverage: Baby Hair Care, Baby Skin Care, Baby Sun Care, Baby Toiletries, Medicated Baby Care, Nappy (Diaper) Rash Treatments. Data coverage: market ...
September 2011
30 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Insecticides in Switzerland
US$ 990.00
... as cancer-causing substances and possible human carcinogens. Euromonitor International's Insecticides in Switzerland market report offers a comprehensive guide to the size and shape ... market is set to change. Product coverage: Electric Insecticides, Insecticide Baits, Insecticide Coils, Other Insecticides, Spray/Aerosol Insecticides. Data coverage: market sizes (historic and forecasts ...
July 2011
17 pages
Novartis vs. Peer group- Growth rate differential to widen going forward
US$ 90.00
Novartis reported solid revenue growth driven by Sandoz, recently launched products and Alcon Acquisition. Going ... shape up in the longer term. Novartis is in better position to return back profits to investors compare to its global peers in unfavorable environment mainly due to its ...
July 2011
2 pages
NOVARTIS, NVA237 ready to enter LAMA market: Spiriva domination under threat!!
US$ 90.00
... daily LAMA), meeting both, primary and the secondary endpoints. NVA237 demonstrated comparable safety and efficacy data vs. PFE’s Spiriva (once ... antimuscarinic side effects is potentially how, NVS might pitch NVA237 against Spiriva. We expect NVA237 to garner upto 25% of the LAMA market growing approximately ...
June 2011
2 pages
ASCO-2011 – RG7204 Vs Ipilimumab : The first line Dilemma persists
US$ 140.00
... the detailed data from phase III pivotal studies on RG7204 and ipilimumab respectively. With the overall survival data on ... comparable, physician is likely to weigh ipilimumab’s superior durability of response compared to RG7204 (19.3m vs 6.7m) on one side with its inferior toxicity profile (56% vs 10% ≤ Grade ...
June 2011
2 pages
Tarcva - EURTAC Data positive: Threat to Iressa in Firstline NSCLC
US$ 140.00
... by 63 % compared to chemotherapy (9.7 m vs 5.2 m). Interim analysis of EURTAC trial showed that Tarceva improved the overall survival by 4 m (22.9 m ... vs 18.8 m) compared to cisplatin chemotherapy. The data poses threat to AZN’s Iressa as it has not demonstrated OS ... lines of EGFR positive advanced NSCLC.
June 2011
2 pages
Health & Wellness Tourism in Switzerland
US$ 990.00
... country is well placed to be a leading player in this industry, not least because VIPs can count on privacy. Euromonitor International's Health and Wellness Tourism in Switzerland report offers ... how the market is set to change. Product coverage: Medical Tourism, Other Health and Wellness Tourism, Spas. Data coverage: market sizes (historic and forecasts ...
April 2011
30 pages
Swiss Market for Dental Prosthetics and CAD/CAM Devices 2011
US$ 4,495.00
... technology is headquartered in Zurich Switzerland. Nobel Biocare is a global leader in dental prosthetics and CAD/CAM technology. There is growing demand among Swiss patients for ... represent the fastest growing segment while the CAD/CAM system market will exhibit high unit growth rates over the forecast period ...
March 2011
88 pages
Swiss Market for Dental Implants and Final Abutments 2011
US$ 4,495.00
... implant rate. Switzerland is also the home country of several major dental implant companies such as Straumann and CAMLOG. The Swiss market is relatively ... companies such as Biomet/3i , DENTSPLY, Nobel Biocare and Straumann lead the market, among many others. This report provides a comprehensive and detailed ...
March 2011
56 pages
Clothing and Footwear Specialist Retailers - Switzerland
US$ 990.00
... , and consequently retailers positioned at the lower-end of the price range suffered less from... Euromonitor International's Clothing and Footwear Specialist Retailers in Switzerland report offers insight into key trends and developments driving the industry. The report examines all retail channels ...
February 2011
89 pages
Grocery Retailers - Switzerland
US$ 990.00
... . The retailer responded to the challenge from Aldi and Lidl with significant price cuts and an increased... Euromonitor International's Grocery Retailers in Switzerland report offers insight into key trends and developments driving the industry. The report examines all retail channels to provide ...
February 2011
90 pages
